Medikamentöse Prävention der KHK: Welche Strategien stehen uns zur Verfügung?

Natalie Arnold; Stefan Blankenberg

doi:10.1055/a-2539-6112

Aktuelle Kardiologie, Table of Contents

Aktuelle Kardiologie 2025; 14(02): 129-135
DOI: 10.1055/a-2539-6112

Kurzübersicht

Medikamentöse Prävention der KHK: Welche Strategien stehen uns zur Verfügung?

Secondary Prevention of Coronary Heart Disease: Novel Therapeutic Concepts

Natalie Arnold

¹Department of Cardiology, University Medical University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland (Ringgold ID: RIN196169)

,

Stefan Blankenberg

¹Department of Cardiology, University Medical University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland (Ringgold ID: RIN196169)

› Author Affiliations

Abstract

Zusammenfassung

Die aktuelle Leitlinie der ESC (European Society of Cardiology) zum chronischen Koronarsyndrom (CCS) bringt einige Neuerungen in der medikamentösen Therapie von CCS-Patienten. Diese betreffen die antithrombotischen, lipidsenkenden, metabolischen, antihypertensiven sowie antiinflammatorischen Grundpfeiler der Therapie. Neben neuen Empfehlungen für eine individuelle antithrombotische Therapie wird erstmalig die Bedeutung einer antiinflammatorischen Medikation bei bestimmten CCS-Patienten zur Reduktion des residuellen Risikos berücksichtigt. Es werden zudem neue Konzepte der antimetabolischen Therapie zur Verbesserung des kardiovaskulären Outcomes vorgestellt. Die Optimierung der medikamentösen Therapieoptionen zur Behandlung der Risikofaktoren in Kombination mit einer modernen Thrombozytenaggregationshemmung würde zu wirksamen und personalisierten Präventionsstrategien für CCS-Patienten führen.

Abstract

The current ESC guideline on chronic coronary syndrome (CCS) introduces several novel therapeutic concepts in the secondary prevention of CCS patients. These include new recommendations for individualised antithrombotic therapy to be considered in specific clinical scenarios. In addition, interventions aimed at reducing the inflammatory burden in all CCS patients are introduced for the first time. Finally, new treatment options for overweight and obese CCS patients are also presented. Optimisation of drug therapy to treat risk factors in combination with modern antiplatelet management would lead to effective and personalised prevention strategies for patients with CCS.

Schlüsselwörter

Sekundärprävention - chronisches Koronarsyndrom - antithrombozytäre Therapie - Inflammation - lipidsenkende Therapie

Keywords

chronic coronary syndrome - lipid-lowering medication - secondary prevention - inflammation - antithrombocytic therapy

Full Text

References

Literatur
1 Jernberg T, Hasvold P, Henriksson M. et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36: 1163-1170
2 Vrints C, Andreotti F, Koskinas KC. et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024; 45: 3415-3537
3 Koo BK, Kang J, Park KW. et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicenter trial. Lancet 2021; 397: 2487-2496
4 Mach F, Baigent C, Catapano AL. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
5 Visseren FLJ, Mach F, Smulders YM. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-3337
6 Nissen SE, Lincoff AM, Brennan D. et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388: 1353-1364
7 Ferri N, Ruscica M, Fazio S. et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. J Clin Med 2024; 13: 943
8 Ridker PM, Everett BM, Thuren T. et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377: 1119-1131
9 Tardif JC, Kouz S, Waters DD. et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019; 381: 2497-2505
10 Nidorf SM, Fiolet ATL, Mosterd A. et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med 2020; 383: 1838-1847
11 Opstal TSJ, Hoogeveen RM, Fiolet ATL. et al. Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy. Circulation 2020; 142: 1996-1998
12 Mazhar F, Faucon AL, Fu EL. et al. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur Heart J 2024; 45: 4719-4730
13 Marx N, Federici M, Schütt K. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 2023; 44: 4043-4140
14 Lincoff AM, Brown-Frandsen K, Colhoun HM. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389: 2221-2232
15 Prosser HC, Peck KY, Dinh D. et al. Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction. Clin Res Cardiol 2022; 111: 776-786